» Articles » PMID: 38563680

Gastrointestinal Microbiota and Metabolites Possibly Contribute to Distinct Pathogenicity of SARS-CoV-2 Proto or Its Variants in Rhesus Monkeys

Abstract

Gastrointestinal (GI) infection is evidenced with involvement in COVID-19 pathogenesis caused by SARS-CoV-2. However, the correlation between GI microbiota and the distinct pathogenicity of SARS-CoV-2 Proto and its emerging variants remains unclear. In this study, we aimed to determine if GI microbiota impacted COVID-19 pathogenesis and if the effect varied between SARS-CoV-2 Proto and its variants. We performed an integrative analysis of histopathology, microbiomics, and transcriptomics on the GI tract fragments from rhesus monkeys infected with SARS-CoV-2 proto or its variants. Based on the degree of pathological damage and microbiota profile in the GI tract, five of SARS-CoV-2 strains were classified into two distinct clusters, namely, the clusters of Alpha, Beta and Delta (ABD), and Proto and Omicron (PO). Notably, the abundance of potentially pathogenic microorganisms increased in ABD but not in the PO-infected rhesus monkeys. Specifically, the high abundance of , , and in ABD virus-infected animals positively correlated with interleukin, integrins, and antiviral genes. Overall, this study revealed that infection-induced alteration of GI microbiota and metabolites could increase the systemic burdens of inflammation or pathological injury in infected animals, especially in those infected with ABD viruses. Distinct GI microbiota and metabolite profiles may be responsible for the differential pathological phenotypes of PO and ABD virus-infected animals. These findings improve our understanding the roles of the GI microbiota in SARS-CoV-2 infection and provide important information for the precise prevention, control, and treatment of COVID-19.

Citing Articles

CHIKV infection drives shifts in the gastrointestinal microbiome and metabolites in rhesus monkeys.

Chen H, Shi J, Tang C, Xu J, Li B, Wang J Microbiome. 2024; 12(1):161.

PMID: 39223641 PMC: 11367899. DOI: 10.1186/s40168-024-01895-w.

References
1.
Wang C, Horby P, Hayden F, Gao G . A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223):470-473. PMC: 7135038. DOI: 10.1016/S0140-6736(20)30185-9. View

2.
Liu Q, Mak J, Su Q, Yeoh Y, Lui G, Ng S . Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022; 71(3):544-552. DOI: 10.1136/gutjnl-2021-325989. View

3.
Kumar A, Faiq M, Pareek V, Raza K, Narayan R, Prasoon P . Relevance of SARS-CoV-2 related factors ACE2 and TMPRSS2 expressions in gastrointestinal tissue with pathogenesis of digestive symptoms, diabetes-associated mortality, and disease recurrence in COVID-19 patients. Med Hypotheses. 2020; 144:110271. PMC: 7487155. DOI: 10.1016/j.mehy.2020.110271. View

4.
Ghosh N, Nandi S, Saha I . A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein. Int Immunopharmacol. 2022; 105:108565. PMC: 8799522. DOI: 10.1016/j.intimp.2022.108565. View

5.
Zhu C, Xiao F, Hong J, Wang K, Liu X, Cai D . EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway. J Virol. 2015; 89(13):6608-18. PMC: 4468487. DOI: 10.1128/JVI.00364-15. View